Home >> Top News >> Hemlibra OK’d for hemophilia A with inhibitors

Hemlibra OK’d for hemophilia A with inhibitors

Print Friendly, PDF & Email

Dec. 27, 2017Genentech announced the FDA’s approval of Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors. Nearly one in three people with severe hemophilia A can develop inhibitors to factor VIII replacement therapies, putting them at greater risk for life-threatening bleeds or repeated bleeds that can cause long-term joint damage. In two of the largest pivotal clinical studies for people with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2), Hemlibra was shown to substantially reduce bleeds in adults and children.

More top news